An open-label trial demonstrates comparable survival outcomes in high-risk systemic sclerosis patients with advanced organ involvement, suggesting viability for treatment.
This adapted regimen showed comparable 3y-OS in patients with advanced organ involvement who would have been excluded from prior trials. While feasibility is demonstrated, aHSCT in this high-risk population remains associated with substantial risk, and efficacy cannot be definitively established. Further studies are warranted.
No takes yet. Share an insight, caveat, or question.
Pecher et al. (2026) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: